

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



KINGWORLD MEDICINES GROUP LIMITED
金活醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code : 01110)

VOLUNTARY ANNOUNCEMENT
SHARE PURCHASE PURSUANT TO THE SHARE AWARD SCHEME

This is a voluntary announcement made by the board (the “**Board**”) of directors (the “**Directors**”) of Kingworld Medicines Group Limited (the “**Company**”).

Reference is made to the announcement of the Company dated 27 August 2019 (the “**Announcement**”) in relation to the adoption of the share award scheme (the “**Share Award Scheme**”) by the Company, the announcement of the Company dated 22 May 2020 and 13 July 2022 in relation to the increase of scheme limit and the announcement of the Company dated 21 January 2022 in relation to the grant of award pursuant to Share Award Scheme. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

The Board wishes to announce that on 7 October 2022, the Trustee purchased an aggregate of 1,000,000 Shares from the market, for the purpose of the Share Award Scheme. The Shares shall constitute part of the Trust Fund and be held by the Trustee for the benefit of the Selected Participants.

Details of the Shares purchased on 7 October 2022 and held by the Trustee on trust are as follows:

Total number of Shares purchased:	1,000,000 Shares
Percentage of the Shares purchased to the existing total number of Shares in issue:	Approximately 0.16%
Average consideration per Share:	Approximately HK\$0.4249
Total consideration of Shares purchased:	HK\$424,949
Balance of Shares held by the Trustee:	15,444,000 Shares

Up to the date of this announcement, 1,556,000 Shares have been awarded to 73 Selected Participants pursuant to the Share Award Scheme. The Board will from time to time review and determine at its absolute discretion such number of Shares to be awarded to the Selected Participants with such vesting conditions as it may deem appropriate and the number of Shares to be further purchased by the Trustee from the market under the Share Award Scheme.

By order of the Board
Kingworld Medicines Group Limited
Zhao Li Sheng
Chairman

Hong Kong, 7 October 2022

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Zhao Li Sheng, Ms. Chan Lok San and Mr. Zhou Xuhua, and three independent non-executive Directors are Mr. Duan Jidong, Mr. Zhang Jianbin and Mr. Wong Cheuk Lam.